CLNN - Clene Presents Phase 2 CNM-Au8 Data at 2024 American Academy of Neurology Annual Meeting

2024-04-17 06:55:40 ET

DENVER, Colo., Apr 17, 2024 ( 247marketnews.com )- Clene Inc. (Nasdaq: CLNN ) presented Phase 2 VISIONARY-MS long term extension (LTE) study results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver. The improved clinical, functional, and structural outcomes associated with daily oral dosing of CNM-Au8 30 mg for up to three years of treatment included evidence supporting repair and remyelinating effects of CNM-Au8 treatment in patients originally randomized to CNM-Au8.

Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, from the University of Sydney, stated, “The development of adjunctive therapies that not only prevent neurodegeneration, but also improve neuronal function with measurable clinical benefit, will fill a major unmet need for people living with MS. In the VISIONARY-MS trial, consistent improvements in multiple clinical and paraclinical endpoints over three years of adjunctive treatment with CNM-Au8 provide clear impetus for a definitive Phase 3 study.”

Dr. Benjamin Greenberg, Head of Medical for Clene, added, “Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials. This is a very exciting data set that gives hope to the millions of people who are suffering from this disabling disease.”

The post Clene Presents Phase 2 CNM-Au8 Data at 2024 American Academy of Neurology Annual Meeting appeared first on 24/7 MarketNews .

For further details see: